A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

• ClinicalTrials.gov Identifier: NCT03711188
• Recruitment Status: Completed
• First Posted: October 18, 2018
• Last Update Posted: April 7, 2022
• Sponsor: Immodulon Therapeutics Ltd
• Information provided by (Responsible Party): Immodulon Therapeutics Ltd

Tracking Information

• First Submitted Date: October 4, 2018
• First Posted Date: October 18, 2018
• Last Update Posted Date: April 7, 2022
• Actual Study Start Date: October 4, 2018
• Actual Primary Completion Date: December 2, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: October 16, 2018)

• Overall Response Rate (ORR) using RECIST 1.1 [ Time Frame: 18 months ]
  ORR is calculated from Best Overall Response recorded during treatment with IMM-101 + nivolumab
• The profile of adverse events experienced [ Time Frame: 18 months ]

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: October 16, 2018)

• Progression free survival (PFS) [ Time Frame: 18 months ]
• Overall survival (OS) [ Time Frame: Approximately 30 months ]
• Overall survival (OS) at one year [ Time Frame: 12 months ]
• Patients with values outside normal range and within normal range at post baseline assessments [ Time Frame: 18 months ]
• Local tolerability measured as injection site reactions [ Time Frame: 18 months ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
• Official Title: A Study of the Safety and Efficacy of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma
• Brief Summary: The purpose of this study is to assess the safety and efficacy of the combination of IMM-101 with nivolumab.
• Detailed Description: This open-label study will assess the safety and efficacy of the combination of IMM-101 with nivolumab in patients with unresectable stage III, or stage IV melanoma who are either treatment-naive (cohort A) or whose disease has progressed during PD-1 blockade (cohort B). Ipilimumab may be used as a subsequent treatment in place of nivolumab alongside IMM-101 for patients in cohort B if their disease progresses on study. Eighteen patients will be enrolled into cohort A and 8 patients into cohort B.
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Melanoma

Intervention

• Drug: Nivolumab
  Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.
  Other Name: Opdivo
• Drug: Ipilimumab
  Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.
  Other Name: Yervoy
• Drug: IMM-101
  A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.

Study Arms

Experimental: IMM-101 (and nivolumab or ipilimumab)

IMM-101 given in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.

Interventions:

• Drug: Nivolumab
• Drug: Ipilimumab
• Drug: IMM-101

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: April 6, 2022): 16
• Original Estimated Enrollment (submitted: October 16, 2018): 26
• Actual Study Completion Date: December 2, 2021
• Actual Primary Completion Date: December 2, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Key Inclusion Criteria:

1. Histologically-confirmed diagnosis of advanced (unresectable Stage III) or metastatic (Stage IV) melanoma.
2. At least one measurable lesion by CT or MRI, according to RECIST 1.1.
3. Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) Performance Status of ≤1 at Day 0.
4. Known BRAF V600 mutation status or consent to BRAF V600 mutation testing during the Screening Period.
5. Prior radiotherapy must have been completed at least 2 weeks prior to study drug administration (Week 0, Visit 1). Prior adjuvant or neoadjuvant melanoma therapy is permitted if it was completed at least 6 weeks prior to enrolment (Week 0, Visit 1), and all related adverse events have resolved or stabilised.
6. Patient is considered suitable for treatment with nivolumab.

For cohort A, the following key inclusion criteria apply:

1. Patient is treatment-naive (i.e. no prior systemic anticancer therapy for unresectable or metastatic melanoma).

For cohort B, the following key inclusion criteria apply:

1. Patient is either currently receiving treatment with an anti-PD-1 therapy (monotherapy or in combination with ipilimumab), for advanced melanoma and has progressive disease by RECIST 1.1 after 4 or more doses; or has previously received at least 4 doses of PD-1 targeted therapy, alone or in combination with ipilimumab, had disease progression by RECIST 1.1 during this therapy and has not received any further therapy for advanced melanoma.

Key Exclusion Criteria:

1. Uveal/ocular melanoma.
2. Active brain metastases or leptomeningeal metastases. Patients with brain metastases are eligible for cohort B of the study only, if these have been treated and there is no MRI evidence of progression for at least 8 weeks after treatment is complete and within 21 days prior to first dose of study treatment administration.
3. Patient has documented history of clinically severe autoimmune disease or a syndrome that requires systemic steroids or immunosuppressive agents.
4. Patient has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or immunosuppressant drugs (such as azathioprine, tacrolimus, cyclosporin) within the 14 days period before the first administration of IMM-101.

For cohort A, patients meeting the following key criteria are also ineligible to participate in this study:

1. Patient has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-PD ligand-1 (PD-L1), anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agent.

For cohort B, patients meeting the following key criteria are also ineligible to participate in this study:

1. Patient has received more than one treatment regimen for advanced (stage III/IV) disease prior to their anti PD-1 therapy.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United Kingdom

Administrative Information

• NCT Number: NCT03711188
• Other Study ID Numbers: IMM-101-015
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Immodulon Therapeutics Ltd
• Original Responsible Party: Same as current
• Current Study Sponsor: Immodulon Therapeutics Ltd
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Alberto Fusi; St George's University Hospitals NHS Foundation Trust

• PRS Account: Immodulon Therapeutics Ltd
• Verification Date: May 2021